• Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Auteur:Bousser, MG; Amarenco, P; Chamorro, A; Fisher, Martin; Ford, Ian; Fox, K.; Hennerici, MG; Mattle, HP; Rothwell, PM; PERFORM Study Investigators, Massimo; Pandolfo,
Informations sur la publication:Cerebrovascular diseases, 27, 5, page (509-518)
Statut de publication:Publié, 2009
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Aged
Aged, 80 and over
Aspirin -- adverse effects
Aspirin -- therapeutic use
Cardiovascular Diseases -- etiology
Cardiovascular Diseases -- prevention & control
Dose-Response Relationship, Drug
Double-Blind Method
Endpoint Determination
International Cooperation
Ischemic Attack, Transient -- complications
Ischemic Attack, Transient -- drug therapy
Middle Aged
Naphthalenes -- adverse effects
Naphthalenes -- therapeutic use
Platelet Aggregation Inhibitors -- adverse effects
Platelet Aggregation Inhibitors -- therapeutic use
Propionic Acids -- adverse effects
Propionic Acids -- therapeutic use
Receptors, Thromboxane -- antagonists & inhibitors
Stroke -- complications
Stroke -- drug therapy
Stroke -- etiology
Stroke -- prevention & control
Treatment Outcome
Note générale:Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't